Sandbox g55: Difference between revisions
Jump to navigation
Jump to search
Gerald Chi- (talk | contribs) mNo edit summary |
Gerald Chi- (talk | contribs) mNo edit summary |
||
| Line 34: | Line 34: | ||
{{PBI|Acanthamoeba}} | {{PBI|Acanthamoeba}} | ||
:* Acanthamoeba species | :* '''Acanthamoeba species''' | ||
::* 1. '''Granulomatous amoebic encephalitis''' | |||
:::* Preferred regimen: | |||
::* 2. '''Acanthamoeba keratitis''' | |||
:::* Preferred regimen: ([[Polyhexamethylene biguanide]] 0.02% topical {{or}} [[Chlorhexidine]] 0.02% topical) {{withorwithout}} ([[Propamidine isethionate]] 0.1% {{or}} [[Hexamidine]] 0.1%) | |||
:::* Note (1): Azole antifungal drugs (Ketoconazole, Itraconazole, Voriconazole) may be considered as oral or topical adjuncts. | |||
:::* Note (2): The duration of therapy for Acanthamoeba keratitis may last six months to a year. | |||
---- | |||
{{PBI|Balamuthia mandrillaris}} | {{PBI|Balamuthia mandrillaris}} | ||
Revision as of 19:22, 22 July 2015
- Enterobacter
Return to Top
-
- 1. Empiric antimicrobial therapy pending in vitro susceptibility
- 1.1 Non–life-threatening infections or MDR-GNB prevalence < 20%
- Preferred regimen: Piperacillin-Tazobactam 3.375 g IV q6h ± Aminoglycosides
- Alternative regimen: Ciprofloxacin 400 mg IV q8–12h
- 1.2 Life-threatening infections or MDR-GNB prevalence > 20%
- Preferred regimen: Meropenem 0.5–1 g IV q8h
- Alternative regimen (1): Colistin AND Meropenem 0.5–1 g IV q8h
- Alternative regimen (2): Colistin AND Imipenem 500 mg IV q6h
- Alternative regimen (3): Colistin AND Doripenem 500 mg IV q8h
- Alternative regimen (4): Colistin AND Ertapenem 1 g IV q24h
- Alternative regimen (5): Colistin AND Fosfomycin 6 g IV q6h
- 2. In vitro susceptibility available
- 2.1 Susceptible to all tested agents
- Preferred regimen: Piperacillin-Tazobactam 3.375 g IV q6h
- Alternative regimen (1): Ciprofloxacin 400 mg IV q8–12h
- Alternative regimen (2): Cefepime 2 g IV q8h (if MIC ≤ 1 μg/mL)
- 2.2 Extended spectrum beta-lactamase (ESBL)-producing Enterobacter spp.
- 2.3 Resistant to all tested agents
- Preferred regimen: Colistin AND Meropenem 0.5–1 g IV q8h
- Alternative regimen (1): Colistin AND Imipenem 500 mg IV q6h
- Alternative regimen (2): Colistin AND Doripenem 500 mg IV q8h
- Alternative regimen (3): Colistin AND Ertapenem 1 g IV q24h
- Alternative regimen (4): Colistin AND Minocycline 100 mg IV q12h
- Acanthamoeba
Return to Top
- Acanthamoeba species
- 1. Granulomatous amoebic encephalitis
- Preferred regimen:
- 2. Acanthamoeba keratitis
- Preferred regimen: (Polyhexamethylene biguanide 0.02% topical OR Chlorhexidine 0.02% topical) ± (Propamidine isethionate 0.1% OR Hexamidine 0.1%)
- Note (1): Azole antifungal drugs (Ketoconazole, Itraconazole, Voriconazole) may be considered as oral or topical adjuncts.
- Note (2): The duration of therapy for Acanthamoeba keratitis may last six months to a year.
- Balamuthia mandrillaris
Return to Top
- Balamuthia mandrillaris
References
- ↑ Sanders, W. E.; Sanders, C. C. (1997-04). "Enterobacter spp.: pathogens poised to flourish at the turn of the century". Clinical Microbiology Reviews. 10 (2): 220–241. ISSN 0893-8512. PMC 172917. PMID 9105752. Check date values in:
|date=(help) - ↑ Jacoby, George A. (2009-01). "AmpC beta-lactamases". Clinical Microbiology Reviews. 22 (1): 161–182. doi:10.1128/CMR.00036-08. ISSN 1098-6618. PMC 2620637. PMID 19136439. Check date values in:
|date=(help) - ↑ Paterson, David L.; Bonomo, Robert A. (2005-10). "Extended-spectrum beta-lactamases: a clinical update". Clinical Microbiology Reviews. 18 (4): 657–686. doi:10.1128/CMR.18.4.657-686.2005. ISSN 0893-8512. PMC 1265908. PMID 16223952. Check date values in:
|date=(help) - ↑ Bartlett, John (2012). Johns Hopkins ABX guide : diagnosis and treatment of infectious diseases. Burlington, MA: Jones and Bartlett Learning. ISBN 978-1449625580.
- ↑ Gilbert, David (2015). The Sanford guide to antimicrobial therapy. Sperryville, Va: Antimicrobial Therapy. ISBN 978-1930808843.